Newer antibacterial drugs for a new century

Bibliography

• Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 2008;52(3):813-21
   PubMed Web of Science ®Google Scholar
• The Global Antibacterials Market: R&D Pipelines, Market Analysis and Competitive Landscape; 28 August 2007
   Google Scholar
• Boucher HW, Talbot GH, Bradley JS, Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48(1):1-12
   PubMed Web of Science ®Google Scholar
• Talbot GH, Bradley J, Edwards JE Jr, Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006;42(5):657-68
   PubMed Web of Science ®Google Scholar
• Outterson K, Samora JB, Keller-Cuda K. Will longer antimicrobial patents improve global public health? Lancet Infect Dis 2007;7(8):559-66
   PubMed Web of Science ®Google Scholar
• Colca JR, McDonald WG, Waldon DJ, Cross-linking in the living cell locates the site of action of oxazolidinone antibiotics. J Biol Chem 2003;278(24):21972-9
   PubMed Web of Science ®Google Scholar
• Lin AH, Murray RW, Vidmar TJ, Marotti KR. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob Agents Chemother 1997;41(10):2127-31
   PubMed Web of Science ®Google Scholar
• Qin Y, Polacek N, Vesper O, The highly conserved LepA is a ribosomal elongation factor that back-translocates the ribosome. Cell 2006;127(4):721-33
   PubMed Web of Science ®Google Scholar
• Leach KL, Swaney SM, Colca JR, The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol Cell 2007;26(3):393-402
   PubMed Web of Science ®Google Scholar
• Wilson DN, Nierhaus KH. The oxazolidinone class of drugs find their orientation on the ribosome. Mol Cell 2007;26(4):460-2
   PubMed Web of Science ®Google Scholar
• French G. Safety and tolerability of linezolid. J Antimicrob Chemother 2003;51(Suppl 2):ii45-53
   PubMedGoogle Scholar
• Lee E, Burger S, Shah J, Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin Infect Dis 2003;37(10):1389-91
   PubMed Web of Science ®Google Scholar
• Brickner SJ, Hutchinson DK, Barbachyn MR, Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J Med Chem 1996;39(3):673-9
   PubMed Web of Science ®Google Scholar
• Jorgensen JH, McElmeel ML, Trippy CW. In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species. Antimicrob Agents Chemother 1997;41(2):465-7
   PubMed Web of Science ®Google Scholar
• Mason EO Jr, Lamberth LB, Kaplan SL. In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 1996;40(4):1039-40
   PubMed Web of Science ®Google Scholar
• Molicotti P, Ortu S, Bua A, In vitro efficacy of linezolid on clinical strains of Mycobacterium tuberculosis and other mycobacteria. New Microbiol 2006;29(4):275-80
   PubMed Web of Science ®Google Scholar
• Brown-Elliott BA, Ward SC, Crist CJ, In vitro activities of linezolid against multiple Nocardia species. Antimicrob Agents Chemother 2001;45(4):1295-7
   PubMed Web of Science ®Google Scholar
• Moylett EH, Pacheco SE, Brown-Elliott BA, Clinical experience with linezolid for the treatment of Nocardia infection. Clin Infect Dis 2003;36(3):313-8
   PubMed Web of Science ®Google Scholar
• Vara Prasad JV. New oxazolidinones. Curr Opin Microbiol 2007;10(5):454-60
   PubMed Web of Science ®Google Scholar
• File JR, T, Bagheri F, Bush L, Desanto J, Markowitz A, Merrick B, A phase 2 study comparing two doses of radezolid to linezolid in adults with Uncomplicated Skin and Skin Structure Infections (uSSSI) (L-1515c). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society of America (IDSA). 46th Annual Meeting; 25 – 28 Oct 2008; Washington DC
   Google Scholar
• Schaadt R, Sweeney D, Shinabarger D, Zurenko G. In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent. Antimicrob Agents Chemother 2009;53(8):3236-9
   PubMed Web of Science ®Google Scholar
• Foleno BD, Abbanat D, Goldschmidt RM, In vitro antibacterial activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457. Antimicrob Agents Chemother 2007;51(1):361-5
   PubMed Web of Science ®Google Scholar
• Livermore DM, Warner M, Mushtaq S, In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci. Antimicrob Agents Chemother 2007;51(3):1112-4
   PubMed Web of Science ®Google Scholar
• Xiong L, Kloss P, Douthwaite S, Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action. J Bacteriol 2000;182(19):5325-31
   PubMed Web of Science ®Google Scholar
• Shaw KJ, Poppe S, Schaadt R, In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother 2008;52(12):4442-7
   PubMed Web of Science ®Google Scholar
• Feng J, Lupien A, Gingras H, Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res 2009;19(7):1214-23
   PubMed Web of Science ®Google Scholar
• Bosso JA. The antimicrobial armamentarium: evaluating current and future treatment options. Pharmacotherapy 2005;25(10 Pt 2):55S-62S
   PubMed Web of Science ®Google Scholar
• Allen NE, Hobbs JN Jr, Nicas TI. Inhibition of peptidoglycan biosynthesis in vancomycin-susceptible and -resistant bacteria by a semisynthetic glycopeptide antibiotic. Antimicrob Agents Chemother 1996;40(10):2356-62
   PubMed Web of Science ®Google Scholar
• Kim SJ, Cegelski L, Stueber D, Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus. J Mol Biol 2008;377(1):281-93
   PubMed Web of Science ®Google Scholar
• Allen NE, LeTourneau DL, Hobbs JN Jr. Molecular interactions of a semisynthetic glycopeptide antibiotic with D-alanyl-D-alanine and D-alanyl-D-lactate residues. Antimicrob Agents Chemother 1997;41(1):66-71
   PubMed Web of Science ®Google Scholar
• Allen NE, LeTourneau DL, Hobbs JN Jr. The role of hydrophobic side chains as determinants of antibacterial activity of semisynthetic glycopeptide antibiotics. J Antibiot (Tokyo) 1997;50(8):677-84
   PubMed Web of Science ®Google Scholar
• Beauregard DA, Williams DH, Gwynn MN, Knowles DJ. Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics. Antimicrob Agents Chemother 1995;39(3):781-5
   PubMed Web of Science ®Google Scholar
• Buckwalter M, Dowell JA. Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J Clin Pharmacol 2005;45(11):1279-87
   PubMed Web of Science ®Google Scholar
• Higgins DL, Chang R, Debabov DV, Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005;49(3):1127-34
   PubMed Web of Science ®Google Scholar
• Lunde CS, Hartouni SR, Janc JW, Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob Agents Chemother 2009;53(8):3375-83
   PubMed Web of Science ®Google Scholar
• Candiani G, Abbondi M, Borgonovi M, In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J Antimicrob Chemother 1999;44(2):179-92
   PubMed Web of Science ®Google Scholar
• Lin G, Credito K, Ednie LM, Appelbaum PC. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob Agents Chemother 2005;49(2):770-2
   PubMed Web of Science ®Google Scholar
• Streit JM, Sader HS, Fritsche TR, Jones RN. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagn Microbiol Infect Dis 2005;53(4):307-10
   PubMed Web of Science ®Google Scholar
• King A, Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J Antimicrob Chemother 2004;53(5):797-803
   PubMed Web of Science ®Google Scholar
• Krause KM, Renelli M, Difuntorum S, In vitro activity of telavancin against resistant gram-positive bacteria. Antimicrob Agents Chemother 2008;52(7):2647-52
   PubMed Web of Science ®Google Scholar
• Saravolatz LD, Pawlak J, L. J. In Vitro Activity of Oritavancin against CA-MRSA, VISA and Daptomycin-non-susceptible Staphylococcus aureus (DNSSA) (C1-187). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA). 46th Annual Meeting; 25th – 28th Oct 2008; Washington DC
   Google Scholar
• Arhin FF, Sarmiento I, Parr TR Jr, Moeck G. Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin. J Antimicrob Chemother 2009;64(4):868-70
   PubMed Web of Science ®Google Scholar
• McKay GA, Beaulieu S, Sarmiento I, In vitro time kill studies of oritavancin against Vancomycin-Intermediate Staphylococcus aureus (VISA) (C1-3717). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA). 46th Annual Meeting; 25 – 28 Oct 2008; Washington DC
   Google Scholar
• McKay GA, Beaulieu S, Arhin FF, Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 2009;63(6):1191-9
   PubMed Web of Science ®Google Scholar
• Raad I, Darouiche R, Vazquez J, Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens. Clin Infect Dis 2005;40(3):374-80
   PubMed Web of Science ®Google Scholar
• Jauregui LE, Babazadeh S, Seltzer E, Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005;41(10):1407-15
   PubMed Web of Science ®Google Scholar
• Martino M. Pfizer withdraws dalbavancin app. Fierce Biotech 2008. Available from: http://www.fiercebiotech.com/story/pfizer-withdraws-dalbavancin-app/2008-09-09 [Last accessed 11 Aug 2009]
   Google Scholar
• Stryjewski ME, O'Riordan WD, Lau WK, Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 2005;40(11):1601-7
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Corey GR, Stryjewski ME, Telavancin for treatment of Hospital-Acquired Pneumonia (HAP) Caused by MRSA and MSSA: the ATTAIN Studies (K-530). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society of America (IDSA). 46th Annual Meeting; 25 – 28 Oct 2008; Washington DC
   Google Scholar
• Corey GR, Rubinstein E, Lalani T, Telavancin for Hospital-Acquired Pneumonia caused by S. aureus: efficacy analysis according to the in vitro susceptibility to vancomycin (K-528). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society of America (IDSA). 46th Annual Meeting; 25 – 28 Oct 2008; Washington DC
   Google Scholar
• Hartman CS, Wasilewski MM, Bates BM. Oritavancin in the treatment of Complicated Skin and Skin Structure Infections (cSSSI): combined results of two phase 3 multinational trials (L-1514). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA). 46th Annual Meeting; 25 – 28 Oct 2008; Washington DC
   Google Scholar
• FDA: Targanta must conduct new oritavancin study. Fierce Biotech 2008. Available from: http://www.fiercebiotech.com/story/fda-targanta-must-conduct- new-oritavancin-study/2008-12-09 [Last accessed 11 Aug 2009]
   Google Scholar
• Carrol J. FDA seeks more telavancin data. Fierce Biotech 2009. Available from: http://www.fiercebiotech.com/story/fda-seeks-more-telavancin-data/2009-02-27 [Last accessed 11 Aug 2009]
   Google Scholar
• Arthur M, Courvalin P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother 1993;37(8):1563-71
   PubMed Web of Science ®Google Scholar
• Walsh CT, Fisher SL, Park IS, Bacterial resistance to vancomycin: five genes and one missing hydrogen bond tell the story. Chem Biol 1996;3(1):21-8
   PubMed Web of Science ®Google Scholar
• Leuthner KD, Cheung CM, Rybak MJ. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006;58(2):338-43
   PubMed Web of Science ®Google Scholar
• Goldstein BP, Draghi DC, Sheehan DJ, Bactericidal activity and resistance development profiling of dalbavancin. Antimicrob Agents Chemother 2007;51(4):1150-4
   PubMed Web of Science ®Google Scholar
• Nilius AM, Ma Z. Ketolides: the future of the macrolides? Curr Opin Pharmacol 2002;2(5):493-500
   PubMed Web of Science ®Google Scholar
• Schlunzen F, Harms JM, Franceschi F, Structural basis for the antibiotic activity of ketolides and azalides. Structure 2003;11(3):329-38
   PubMed Web of Science ®Google Scholar
• Capobianco JO, Cao Z, Shortridge VD, Studies of the novel ketolide ABT-773: transport, binding to ribosomes, and inhibition of protein synthesis in Streptococcus pneumoniae. Antimicrob Agents Chemother 2000;44(6):1562-7
   PubMed Web of Science ®Google Scholar
• Champney WS, Pelt J. The ketolide antibiotic ABT-773 is a specific inhibitor of translation and 50S ribosomal subunit formation in Streptococcus pneumoniae cells. Curr Microbiol 2002;45(3):155-60
   PubMed Web of Science ®Google Scholar
• Garza-Ramos G, Xiong L, Zhong P, Mankin A. Binding site of macrolide antibiotics on the ribosome: new resistance mutation identifies a specific interaction of ketolides with rRNA. J Bacteriol 2001;183(23):6898-907
   PubMed Web of Science ®Google Scholar
• Davies TA, Ednie LM, Hoellman DM, Antipneumococcal activity of ABT-773 compared to those of 10 other agents. Antimicrob Agents Chemother 2000;44(7):1894-9
   PubMed Web of Science ®Google Scholar
• Shortridge VD, Zhong P, Cao Z, Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and -resistant streptococci and staphylococci. Antimicrob Agents Chemother 2002;46(3):783-6
   PubMed Web of Science ®Google Scholar
• Shlaes DM, Moellering RC. Telithromycin and the FDA: implications for the future. Lancet Infect Dis 2008;8(2):83-5
   PubMed Web of Science ®Google Scholar
• Milanesio NA, English ML, Fredericks CE, A comparative study of the safety and efficacy of cethromycin (CER) to clarithromycin (CLR) for the treatment of Community Acquired Pneumonia (CAP) in adults (CL05-001). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and Infectious Disease Society of America (IDSA). 46th Annual Meeting; 25 – 28 Oct 2008; Washington DC
   Google Scholar
• Bonnefoy A, Girard AM, Agouridas C, Chantot JF. Ketolides lack inducibility properties of MLS(B) resistance phenotype. J Antimicrob Chemother 1997;40(1):85-90
   PubMed Web of Science ®Google Scholar
• Douthwaite S, Jalava J, Jakobsen L. Ketolide resistance in Streptococcus pyogenes correlates with the degree of rRNA dimethylation by Erm. Mol Microbiol 2005;58(2):613-22
   PubMed Web of Science ®Google Scholar
• Rantala M, Haanpera-Heikkinen M, Lindgren M, Streptococcus pneumoniae isolates resistant to telithromycin. Antimicrob Agents Chemother 2006;50(5):1855-8
   PubMed Web of Science ®Google Scholar
• Wolter N, Smith AM, Farrell DJ, Telithromycin resistance in Streptococcus pneumoniae is conferred by a deletion in the leader sequence of erm(B) that increases rRNA methylation. Antimicrob Agents Chemother 2008;52(2):435-40
   PubMed Web of Science ®Google Scholar
• Gentry DR, Holmes DJ. Selection for high-level telithromycin resistance in Staphylococcus aureus yields mutants resulting from an rplB-to-rplV gene conversion-like event. Antimicrob Agents Chemother 2008;52(3):1156-8
   PubMed Web of Science ®Google Scholar
• Chopra I. Glycylcyclines: third-generation tetracycline antibiotics. Curr Opin Pharmacol 2001;1(5):464-9
   PubMedGoogle Scholar
• Petersen PJ, Jacobus NV, Weiss WJ, In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999;43(4):738-44
   PubMed Web of Science ®Google Scholar
• Sum PE, Petersen P. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg Med Chem Lett 1999;9(10):1459-62
   PubMed Web of Science ®Google Scholar
• Olson MW, Ruzin A, Feyfant E, Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother 2006;50(6):2156-66
   PubMed Web of Science ®Google Scholar
• Bergeron J, Ammirati M, Danley D, Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother 1996;40(9):2226-8
   PubMed Web of Science ®Google Scholar
• Rasmussen BA, Gluzman Y, Tally FP. Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines. Antimicrob Agents Chemother 1994;38(7):1658-60
   PubMed Web of Science ®Google Scholar
• Biedenbach DJ, Beach ML, Jones RN. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases. Diagn Microbiol Infect Dis 2001;40(4):173-7
   PubMed Web of Science ®Google Scholar
• Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother 2001;45(9):2604-8
   PubMed Web of Science ®Google Scholar
• Gales AC, Jones RN. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis 2000;36(1):19-36
   PubMed Web of Science ®Google Scholar
• Boucher HW, Wennersten CB, Eliopoulos GM. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria. Antimicrob Agents Chemother 2000;44(8):2225-9
   PubMed Web of Science ®Google Scholar
• Tafur JD, Torres JA, Correa A, Multicenter evaluation of in vitro activity of tigecycline against carbapenemase producing gram negative isolates from Colombia (C1-3818). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and Infectious Disease Society of America (IDSA). 46th Annual Meeting; 25 – 28 Oct 2008; Washington DC
   Google Scholar
• Lefort A, Lafaurie M, Massias L, Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob Agents Chemother 2003;47(1):216-22
   PubMed Web of Science ®Google Scholar
• Babinchak T, Ellis-Grosse E, Dartois N, The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005;41(Suppl 5):S354-67
   PubMedGoogle Scholar
• Ellis-Grosse EJ, Babinchak T, Dartois N, The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005;41(Suppl 5):S341-53
   PubMed Web of Science ®Google Scholar
• Bergallo C, Jasovich A, Teglia O, Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis 2009;63(1):52-61
   PubMed Web of Science ®Google Scholar
• Florescu I, Beuran M, Dimov R, Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008;62(Suppl 1):i17-28
   PubMedGoogle Scholar
• Vasilev K, Reshedko G, Orasan R, A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother 2008;62(Suppl 1):i29-40
   PubMedGoogle Scholar
• Arbeit RD, Roberts JA, Forsythe AR, Safety and efficacy of PTK 0796: results of the phase 2 study in complicated skin and skin structure infections following iv and oral step-down therapy (L-1515b). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society of America (IDSA). 46th Annual Meeting; 25 – 28 Oct 2008; Washington DC
   Google Scholar
• Ruzin A, Keeney D, Bradford PA. AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii. Antimicrob Agents Chemother 2005;49(2):791-3
   PubMed Web of Science ®Google Scholar
• Visalli MA, Murphy E, Projan SJ, Bradford PA. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob Agents Chemother 2003;47(2):665-9
   PubMed Web of Science ®Google Scholar
• Poole K. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 2005;56(1):20-51
   PubMed Web of Science ®Google Scholar
• FDA Approves New Drug to Treat Complicated Urinary Tract and Intra-Abdominal Infections. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ 2007/ucm109010.htm [Last accessed 11 Aug 2009]. 2007
   Google Scholar
• Jones RN, Sader HS, Fritsche TR. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms. Diagn Microbiol Infect Dis 2005;52(1):71-4
   PubMed Web of Science ®Google Scholar
• Yang Y, Bhachech N, Bush K. Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by beta-lactamases. J Antimicrob Chemother 1995;35(1):75-84
   PubMed Web of Science ®Google Scholar
• Davies TA, Shang W, Bush K, Flamm RK. Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008;52(4):1510-2
   PubMed Web of Science ®Google Scholar
• Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin Microbiol Infect 2005;11(12):974-84
   PubMed Web of Science ®Google Scholar
• Jones RN, Huynh HK, Biedenbach DJ, Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother 2004;54(1):144-54
   PubMed Web of Science ®Google Scholar
• Chastre J, Wunderink R, Prokocimer P, Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008;36(4):1089-96
   PubMed Web of Science ®Google Scholar
• Rea-Neto A, Niederman M, Lobo SM, Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin 2008;24(7):2113-26
   PubMed Web of Science ®Google Scholar
• FDA Asks for More Information Before Sanctioning J&J PRD's Drug for Hospital-Acquired Pneumonia Genetics Engineering & Biotechnology News. August 21, 2008
   Google Scholar
• Livermore DM, Mushtaq S, Warner M. Activity of the anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanisms. J Antimicrob Chemother 2009;64(2):330-5
   PubMed Web of Science ®Google Scholar
• Protez. Safety, Potential Efficacy, and Pharmacokinetics of PZ-601 in the Treatment of Complicated Skin and Skin Structure Infection. Available from: www.clinicaltrials.gov (Clinical Trial identifier number NCT00671580)
   Google Scholar
• Bassetti M, Righi E, Viscoli C. Novel beta-lactam antibiotics and inhibitor combinations. Expert Opin Investig Drugs 2008;17(3):285-96
   PubMed Web of Science ®Google Scholar
• Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 2007;20(3):440-58
   PubMed Web of Science ®Google Scholar
• Santoro C, Abbanat D, Bush K, Flamm RK. Characterization of resistance to doripenem, meropenem and imipenem in pseudomonas aeruginosa (A-028). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA). 46th Annual Meeting; 25 – 28 Oct 2008; Washington DC
   Google Scholar
• Hebeisen P, Heinze-Krauss I, Angehrn P, In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother 2001;45(3):825-36
   PubMed Web of Science ®Google Scholar
• Kosowska K, Hoellman DB, Lin G, Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005;49(5):1932-42
   PubMed Web of Science ®Google Scholar
• Queenan AM, Shang W, Kania M, Interactions of ceftobiprole with beta-lactamases from molecular classes A to D. Antimicrob Agents Chemother 2007;51(9):3089-95
   PubMed Web of Science ®Google Scholar
• Amsler KM, Davies TA, Shang W, In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections. Antimicrob Agents Chemother 2008;52(9):3418-23
   PubMed Web of Science ®Google Scholar
• Noel GJ, Bush K, Bagchi P, A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008;46(5):647-55
   PubMed Web of Science ®Google Scholar
• Noel GJ, Strauss RS, Amsler K, Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother 2008;52(1):37-44
   PubMed Web of Science ®Google Scholar
• Moisan H, Pruneau M, Malouin F. Binding of ceftaroline (CPT) to Penicillin-Binding Proteins (PBPs) of Streptococcus pneumoniae (SPN) and Methicillin-Resistant Staphylococcus aureus (MRSA) (C1-183). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society of America (IDSA). 46th Annual Meeting; 25 – 28 Oct 2008; Washington DC
   Google Scholar
• Villegas-Estrada A, Lee M, Hesek D, Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics. J Am Chem Soc 2008;130(29):9212-3
   PubMed Web of Science ®Google Scholar
• Corey GR, Wilcox M, Talbot GH, CANVAS-1: randomized, double-blinded, phase 3 study (p903-06) of the efficacy and safety of ceftaroline vs. vancomycin plus aztreonam in Complicated Skin and Skin Structure Infections (cSSSI) (L-1515a). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society of America (IDSA). 46th Annual Meeting; 25 – 28 Oct 2008; Washington DC
   Google Scholar
• Vidaillac C, Leonard SN, Sader HS, In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009;53(6):2360-6
   PubMed Web of Science ®Google Scholar
• Oefner C, Bandera M, Haldimann A, Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity. J Antimicrob Chemother 2009;63(4):687-98
   PubMed Web of Science ®Google Scholar
• Schneider P, Hawser S, Islam K. Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg Med Chem Lett 2003;13(23):4217-21
   PubMed Web of Science ®Google Scholar
• Kohlhoff SA, Roblin PM, Reznik T, In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae. Antimicrob Agents Chemother 2004;48(5):1885-6
   PubMed Web of Science ®Google Scholar
• Sader HS, Fritsche TR, Islam K, Antimicrobial activity of iclaprim tested against recent S. aureus clinical isolates: results from the International Study of Iclaprim susceptibility. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 17 – 20 Sept 2007; Chicago, IL (abstract E-902)
   Google Scholar
• Hadvary P, Stevens D, Solonets M, Clinical efficacy of iclaprim in Complicated Skin and Skin Structure Infection (cSSSI): results of combined ASSIST Phase III studies (L-1512). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society of America (IDSA). 46th Annual Meeting; 25 – 28 Oct 2008; Washington DC
   Google Scholar
• FDA Issues Complete Response Letter For Iclaprim. Medical News Today. Available from: http://www.medicalnewstoday.com/articles/135981.php [Last accessed 11 Aug 2009]
   Google Scholar
• Goldstein EJ, Citron DM, Merriam CV, Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic gram-positive species, actinomycetes, and lactobacilli. Antimicrob Agents Chemother 2005;49(1):408-13
   PubMed Web of Science ®Google Scholar
• Mabe S, Champney WS. A comparison of a new oral streptogramin XRP 2868 with quinupristin-dalfopristin against antibiotic-resistant strains of Haemophilus influenzae, Staphylococcus aureus, and Streptococcus pneumoniae. Curr Microbiol 2005;51(6):363-6
   PubMed Web of Science ®Google Scholar
• Dupuis M, Leclercq R. Activity of a new oral streptogramin, XRP2868, against gram-positive cocci harboring various mechanisms of resistance to streptogramins. Antimicrob Agents Chemother 2006;50(1):237-42
   PubMed Web of Science ®Google Scholar
• Gilles HM, Hoffman PS. Treatment of intestinal parasitic infections: a review of nitazoxanide. Trends Parasitol 2002;18(3):95-7
   PubMed Web of Science ®Google Scholar
• Musher DM, Logan N, Hamill RJ, Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006;43(4):421-7
   PubMed Web of Science ®Google Scholar
• Rossignol JF, Abu-Zekry M, Hussein A, Santoro MG. Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial. Lancet 2006;368(9530):124-9
   PubMed Web of Science ®Google Scholar
• Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 2009;136(3):856-62
   PubMed Web of Science ®Google Scholar
• Hoffman PS, Sisson G, Croxen MA, Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni. Antimicrob Agents Chemother 2007;51(3):868-76
   PubMed Web of Science ®Google Scholar
• Sisson G, Goodwin A, Raudonikiene A, Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori. Antimicrob Agents Chemother 2002;46(7):2116-23
   PubMed Web of Science ®Google Scholar
• Muller J, Naguleswaran A, Muller N, Hemphill A. Neospora caninum: functional inhibition of protein disulfide isomerase by the broad-spectrum anti-parasitic drug nitazoxanide and other thiazolides. Exp Parasitol 2008;118(1):80-8
   PubMed Web of Science ®Google Scholar
• Muller J, Wastling J, Sanderson S, A novel Giardia lamblia nitroreductase, GlNR1, interacts with nitazoxanide and other thiazolides. Antimicrob Agents Chemother 2007;51(6):1979-86
   PubMed Web of Science ®Google Scholar
• Ackermann G, Loffler B, Adler D, Rodloff AC. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother 2004;48(6):2280-2
   PubMed Web of Science ®Google Scholar
• Louie T, Miller M, Donskey C, Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother 2009;53(1):223-8
   PubMed Web of Science ®Google Scholar
• Huband MD, Gootz TD, Cohen MA, In vitro antibacterial activity of sulopenem: a new oral penem antimicrobial versus recent bacterial clinical isolates (F1-344). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society of America (IDSA). 46th Annual Meeting; 25 – 28 Oct 2008; Washington DC
   Google Scholar
• Marra A, Lamb L, Medina I, In vivo efficacy of novel prodrugs of sulopenem (F1-351). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society of America (IDSA). 46th Annual Meeting; 25 – 28 Oct 2008; Washington DC
   Google Scholar
• Hermesh O, Page MGP, Carmeli Y, Navon-Venezia S. Efficacy of BAL30376, a New Monobactam/ beta-Lactamase Inhibitor Combination, against Pseudomonas aeruginosa (PA) (F1-1166). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and Infectious Disease Society of America (IDSA). 46th Annual Meeting; 25 – 28 Oct 2008; Washington DC
   Google Scholar
• Hofer B, Miller C, Desarbre E, Page MGP. In vitro activity of the siderophore monobactam BAL30072 against multi-resistant non-fermenting gram-negative Pathogens (F1-1175). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and Infectious Disease Society of America (IDSA). 46th Annual Meeting; 25 – 28 Oct 2008; Washington DC
   Google Scholar
• Page MGP. Beta-Lactams (56F1-804). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and Infectious Disease Society of America (IDSA) 46th Annual Meeting; 25 – 28 Oct 2008; Washington DC
   Google Scholar
• Endimiani A, Choudhary Y, Bonomo RA. In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob Agents Chemother 2009;53(8):3599-601
   PubMed Web of Science ®Google Scholar
• Novexel. Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections. Available from: www.clinicaltrials.gov (Clinical Trial identifier number NCT00690378)
   Google Scholar
• Petersen PJ, Jones CH, Venkatesan AM, Bradford PA. In vitro activities of piperacillin in combination with bli-489 and comparative antibacterial agents against recent clinical isolates. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and Infectious Disease Society of America (IDSA). 46th Annual Meeting; 25 – 28 Oct 2008; Washington DC (abstract F1-1168)
   Google Scholar
• Foleno BD, Morrow BJ, Wira E, Broad spectrum in vitro activity of JNJ-Q2, a new fluoroquinolone (F1-2033). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society of America (IDSA). 46th Annual Meeting; 25 – 28 Oct 2008; Washington DC
   Google Scholar
• Kresken M, Korber-Irrgang B, Labischinski H, Stubbings W. Effect of pH on the in vitro activity of finafloxacin against gram-negative and gram-positive bacteria (F1-2037). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society of America (IDSA). 46th Annual Meeting; 25 – 28 Oct 2008; Washington DC
   Google Scholar
• Haydon DJ, Stokes NR, Ure R, An inhibitor of FtsZ with potent and selective anti-staphylococcal activity. Science 2008;321(5896):1673-5
   PubMed Web of Science ®Google Scholar
• Lock RL, Harry EJ. Cell-division inhibitors: new insights for future antibiotics. Nat Rev Drug Discov 2008;7(4):324-38
   PubMed Web of Science ®Google Scholar
• Li X, Hilgers M, Gc K, Discovery and SAR of a novel series of pyrimidine antibacterials targeting Methionyl-tRNA Synthase (MetRS) (F1-334). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society of America (IDSA). 46th Annual Meeting; 25 – 28 Oct 2008; Washington DC
   Google Scholar
• Denis A, Faivre F, Bonvin Y, Design, synthesis and antibacterial properties of new potent aryloxy-phenol FabI inhibitors (F1-330). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA). 46th Annual Meeting; 25 – 28 Oct 2008; Washington DC
   Google Scholar
• Escaich S, Fischer S, Soulama C, MUT37307 a novel antibacterial against methicillin resistant staphylococci (F1-331). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society of America (IDSA). 46th Annual Meeting; 25 – 28 Oct 2008; Washington DC
   Google Scholar
• Green O, Ni H, Singh A, Novel DNA gyrase inhibitors: structure-guided discovery and optimization of pyrrolamides (F1-2025). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society of America (IDSA). 46th Annual Meeting; 25 – 28 Oct 2008; Washington DC
   Google Scholar
• Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 2006;24(12):1551-7
   PubMed Web of Science ®Google Scholar
• Su Z, Honek JF. Emerging bacterial enzyme targets. Curr Opin Investig Drugs 2007;8(2):140-9
   PubMed Web of Science ®Google Scholar
• Clatworthy AE, Pierson E, Hung DT. Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol 2007;3(9):541-8
   PubMed Web of Science ®Google Scholar
• Liu CI, Liu GY, Song Y, A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science 2008;319(5868):1391-4
   PubMed Web of Science ®Google Scholar
• Thakur JK, Arthanari H, Yang F, A nuclear receptor-like pathway regulating multidrug resistance in fungi. Nature 2008;452(7187):604-9
   PubMed Web of Science ®Google Scholar
• Hawser S, Lociuro S, Islam K. Dihydrofolate reductase inhibitors as antibacterial agents. Biochem Pharmacol 2006;71(7):941-8
   PubMed Web of Science ®Google Scholar
• Negrea A, Bjur E, Ygberg SE, Salicylidene acylhydrazides that affect type III protein secretion in Salmonella enterica serovar typhimurium. Antimicrob Agents Chemother 2007;51(8):2867-76
   PubMed Web of Science ®Google Scholar
• Kauppi AM, Nordfelth R, Uvell H, Targeting bacterial virulence: inhibitors of type III secretion in Yersinia. Chem Biol 2003;10(3):241-9
   PubMed Web of Science ®Google Scholar
• Escaich S. Antivirulence as a new antibacterial approach for chemotherapy. Curr Opin Chem Biol 2008;12(4):400-8
   PubMed Web of Science ®Google Scholar
• Rasko DA, Moreira CG, Li de R, Targeting QseC signaling and virulence for antibiotic development. Science 2008;321(5892):1078-80
   PubMed Web of Science ®Google Scholar
• Rao SP, Alonso S, Rand L, The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2008;105(33):11945-50
   PubMed Web of Science ®Google Scholar
• Rustomjee R, Diacon AH, Allen J, Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 2008;52(8):2831-5
   PubMed Web of Science ®Google Scholar
• Diacon AH, Pym A, Grobusch M, The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009;360(23):2397-405
   PubMed Web of Science ®Google Scholar
• Liu PT, Stenger S, Li H, Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006;311(5768):1770-3
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Adamis T, Laoutaris G, Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2004;48(1):93-9
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Pechere JC, Routsi C, Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis 2008;46(8):1157-64
   PubMed Web of Science ®Google Scholar
• Kuijl C, Savage ND, Marsman M, Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. Nature 2007;450(7170):725-30
   PubMed Web of Science ®Google Scholar
• Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer 2006;118(7):1591-602
   PubMed Web of Science ®Google Scholar
• Mbulaiteye SM, Hisada M, El-Omar EM. Helicobacter pylori-associated global gastric cancer burden. Front Biosci 2009;14:1490-504
   Web of Science ®Google Scholar
• Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007;6(1):29-40
   PubMed Web of Science ®Google Scholar
• O'Shea R, Moser HE. Physicochemical properties of antibacterial compounds: implications for drug discovery. J Med Chem 2008;51(10):2871-8
   PubMed Web of Science ®Google Scholar
• Macielag MJ. How can we improve our anti-infective compound libraries? (936) 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society of America (IDSA). 46th Annual Meeting; 25 – 28 Oct 2008; Washington DC
   Google Scholar
• Payne DJ. Microbiology. Desperately seeking new antibiotics. Science 2008;321(5896):1644-5
   PubMed Web of Science ®Google Scholar
• Carter G. Are natural products still a viable source for new antimicrobial agents? (87F1-937). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society of America (IDSA). 46th Annual Meeting; 25 – 28 Oct 2008; Washington DC
   Google Scholar
• Kaeberlein T, Lewis K, Epstein SS. Isolating ‘uncultivable’ microorganisms in pure culture in a simulated natural environment. Science 2002;296(5570):1127-9
   PubMed Web of Science ®Google Scholar
• Aoki N, Tateda K, Kikuchi Y, Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 2009;63(3):534-42
   PubMed Web of Science ®Google Scholar
• Gounden R, Bamford C, van Zyl-Smit R, Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections. BMC Infect Dis 2009;9:26
   PubMed Web of Science ®Google Scholar
• Montero M, Horcajada JP, Sorli L, Effectiveness and safety of colistin for the treatment of multidrug-resistant pseudomonas aeruginosa infections. Infection 2009;37(5):461-5
   Google Scholar
• Pearson S. Superbugs vs Superdrugs: race goes on. Genet Eng Biotechnol News 2008;28(11):64-6
   Web of Science ®Google Scholar
• Carmody LA, Gill JJ, Gonzalez CF, Bacteriophage therapy in a mouse model of burkholderia infection. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and Infectious Disease Society of America (IDSA). 46th Annual Meeting; 25 – 28 Oct 2008; Washington DC (abstract: F1-3955)
   Google Scholar
• Davies J. Inactivation of antibiotics and the dissemination of resistance genes. Science 1994;264(5157):375-82
   PubMed Web of Science ®Google Scholar
• Tarkkanen AM, Heinonen T, Jogi R, P1A recombinant beta-lactamase prevents emergence of antimicrobial resistance in gut microflora of healthy subjects during intravenous administration of ampicillin. Antimicrob Agents Chemother 2009;53(6):2455-62
   PubMed Web of Science ®Google Scholar
• Asahina Y, Nagae O, Sato T, AM-3005: synthesis and in vitro antibacterial activity of novel mutilin-quinolone hybrid antibacterial agent (F1-2030). 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society of America (IDSA). 46th Annual Meeting; 25 – 28 Oct 2008; Washington DC
   Google Scholar
• Robertson GT, Bonventre EJ, Doyle TB, In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. Antimicrob Agents Chemother 2008;52(7):2313-23
   PubMed Web of Science ®Google Scholar
• Robertson GT, Bonventre EJ, Doyle TB, In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci. Antimicrob Agents Chemother 2008;52(7):2324-34
   PubMed Web of Science ®Google Scholar
• Meers P, Neville M, Malinin V, Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother 2008;61(4):859-68
   PubMed Web of Science ®Google Scholar
• Sabet M, Miller CE, Nolan TG, Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009;53(9):3923-8
   PubMed Web of Science ®Google Scholar
• Bayer. Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis. Available from: www.clinicaltrials.gov (Clinical Trial identifier number NCT00503490)
   Google Scholar
• Mpex. Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis. Available from: www.clinicaltrials.gov
   Google Scholar
• Baker M. Anti-infective antibodies: finding the path forward. Nat Biotechnol 2006;24(12):1491-3
   PubMed Web of Science ®Google Scholar
• Projan SJ. Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 2003;6(5):427-30
   PubMed Web of Science ®Google Scholar
• Strategies to Address Antimicrobial Resistance. Available from: http://www.idsociety.org/STAARAct.htm [Last accessed 18 Aug 2009]
   Google Scholar